Denali Therapeutics
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $3,604 | $0 | $0 | $0 |
Gross Profit | -2,845 | -2,866 | -101,950 | |
EBITDA | -130,541 | -125,602 | -124,665 | -123,040 |
EBIT | -128,447 | -128,447 | -126,902 | |
Net Income | -127,553 | -128,447 | -128,549 | -126,902 |
Net Change In Cash | 3,604 | 0 | 0 | 0 |
Free Cash Flow | -231,477 | -133,670 | -100,062 | -105,918 |
Cash | 201,530 | 387,626 | 205,326 | 90,963 |
Basic Shares | 187,314 | 186,636 | 175,458 | 172,421 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $330,531 | $108,463 |
Gross Profit | -11,183 | -7,795 | 330,531 | 108,463 |
EBITDA | -497,626 | -492,886 | -128,468 | -315,587 |
EBIT | -512,438 | -501,878 | -145,194 | -325,970 |
Net Income | -512,540 | -422,773 | -145,224 | -325,991 |
Net Change In Cash | 0 | 0 | 330,531 | 108,463 |
Free Cash Flow | -422,102 | -363,606 | -370,930 | -262,549 |
Cash | 205,326 | 174,960 | 127,106 | 218,044 |
Basic Shares | 175,458 | 164,473 | 137,370 | 125,530 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.68 |
2026-03-31 | -$0.69 |
2025-12-31 | -$0.73 |
2025-09-30 | -$0.74 |